Belgian researchers create extraembryonic mesoderm cells
Researchers from KU Leuven for the first time have produced human cells able to mimic the molecular mechanisms of early human embryogenesis and related defects.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2080 entries already.
Entries by Thomas Gabrielczyk
SARS-CoV-2 infection triggers chronic fatigue syndrome
A small prospective study among mid-aged people has demonstrated that a mild SARS-CoV-2 infection triggers ME/CF in 50% of the study population.<button lang="en-GB" aria-description="Klicken, um Alternative zu verwenden">
</button>
Danish Bactolife A/S grabs funding
Swedish food and feed supplement specialist Bactolife A/S has received US$5m in funding from the Bill & Melinda Gates Foundation to address gastrointestinal infections.
Moderna launches patent dispute with BioNTech/Pfizer
For the second time within a short period of time, a competitor has sued the mRNA vaccine developer BioNtechPfizer for patent infringement.
Belgian eTheRNA raises €39m in Series B2 financing
Moderna co-founder Kenneth Chien and Novalis LifeSciences LLC are the lead investors of a €39m Series B2 financing in eTheRNA.
Kinarus announces CHF 20 million convertible bond issue
Kinarus Therapeutics Holding AG has raised US$20m in financing through the issuance of convertible bonds to YA II PN, Ltd.
Cancer: Western life style is a killer
A study in the scientific journal The Lancet shows that half of all global cancer deaths are due to life style-related risk factors such as smoking and alcohol use.
Ryvu Therapeutics bags €22m from EIB
Polish cancer drug developer, Ryvu Therapeutics, has received €22m funding from the European Investment Bank via its venture debt instrument.
Largest beer brewer to use sustainable PEF bottles
Avantium and AmBev, part of AB InBev Group, have inked an agreement on PEF for soft drink bottles.
Vector Biopharma kicks of with CHF30m Series A financing
With a Series A funding of CHF 30m from Versant Ventures, Vector Biopharma AG set out to solve several of the current gene delivery problems.